Therapeutic Asset Ratings

210 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Benadryl Glioblastoma	SignPath Pharma, Inc.	P1/2	CCC (49)
Fludarabine Glioblastoma	Beijing Biotech	P1/2	CCC (49)
msc11fcd Glioblastoma	CHA University	P1/2	CCC (49)
Sulfasalazine Glioblastoma	University of Zurich	P1/2	CCC (49)
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE Glioblastoma	Universidad Central del Caribe	P2	CCC (48)
Apixaban Glioblastoma	University of Vermont Medical Center	P2	CCC (48)
bpm31510 Glioblastoma	BPGbio	P2	CCC (48)
Clindamycin Glioblastoma	Memorial Sloan Kettering Cancer Center	P2	CCC (48)
erc1671 Glioblastoma	Epitopoietic Research Corporation	P2	CCC (48)
Fluzoparib Glioblastoma	Tongji Hospital	P2	CCC (48)
Igv-001 Cell Immunotherapy Glioblastoma	Imvax	P2	CCC (48)
Incagn01876 Glioblastoma	University of Pennsylvania	P2	CCC (48)
Nabiximols Glioblastoma	University of Birmingham	P2	CCC (48)
Neratinib Glioblastoma	Patrick Wen, MD	P2	CCC (48)
Pd-L1 T-Hank Glioblastoma	ImmunityBio, Inc.	P2	CCC (48)
Pemigatinib Glioblastoma	Incyte Corporation	P2	CCC (48)
PHYTONADIONE, (E)-(±)- Glioblastoma	BPGbio	P2	CCC (48)
qbs10072s Glioblastoma	Patrick Wen, MD	P2	CCC (48)
TRASTUZUMAB Glioblastoma	Patrick Wen, MD	P2	CCC (48)
Trastuzumab Deruxtecan Glioblastoma	Memorial Sloan Kettering Cancer Center	P2	CCC (48)
Trastuzumab Emtansine Glioblastoma	Patrick Wen, MD	P2	CCC (48)
Triamcinalone Glioblastoma	Memorial Sloan Kettering Cancer Center	P2	CCC (48)
Vortioxetine Glioblastoma	University of Zurich	P2	CCC (48)
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD ANTIGEN CD27) (HUMAN MONOCLONAL CDX-1127 CLONE 1F5 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL CDX-1127 CLONE 1F5 .KAPPA.-CHAIN, DIMER Glioblastoma	Annick Desjardins, MD	P2	CC (47)
Methimazole Glioblastoma	Case Comprehensive Cancer Center	P2	CC (46)

Showing 76 to 100 of 210 assets

PreviousPage 4 of 9Next